219 related articles for article (PubMed ID: 32214807)
1. Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.
Hei Y; Teng B; Zeng Z; Zhang S; Li Q; Pan J; Luo Z; Xiong C; Wei S
Int J Nanomedicine; 2020; 15():1677-1691. PubMed ID: 32214807
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD-L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment.
Hei Y; Chen Y; Li Q; Mei Z; Pan J; Zhang S; Xiong C; Su X; Wei S
Small; 2022 Mar; 18(9):e2105118. PubMed ID: 34915595
[TBL] [Abstract][Full Text] [Related]
3. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity.
Gu Z; Wang Q; Shi Y; Huang Y; Zhang J; Zhang X; Lin G
J Control Release; 2018 Sep; 286():369-380. PubMed ID: 30096401
[TBL] [Abstract][Full Text] [Related]
5. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.
Zou MZ; Liu WL; Li CX; Zheng DW; Zeng JY; Gao F; Ye JJ; Zhang XZ
Small; 2018 Jul; 14(28):e1801120. PubMed ID: 29882235
[TBL] [Abstract][Full Text] [Related]
6. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
8. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
9. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
11. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
12. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
15. APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.
Peng Q; Zhu X; Li C; Xin P; Zheng Y; Liu S
Aging (Albany NY); 2021 Feb; 13(5):7199-7210. PubMed ID: 33653969
[TBL] [Abstract][Full Text] [Related]
16. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
17. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Xiong W; Qi L; Jiang N; Zhao Q; Chen L; Jiang X; Li Y; Zhou Z; Shen J
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8026-8041. PubMed ID: 33577301
[TBL] [Abstract][Full Text] [Related]
18. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
19. Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer.
Zhang R; Song X; Liang C; Yi X; Song G; Chao Y; Yang Y; Yang K; Feng L; Liu Z
Biomaterials; 2017 Sep; 138():13-21. PubMed ID: 28550753
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
